Published in Medical Letter on the CDC and FDA, September 9th, 2007
Warfarin (also called Coumadin) is a drug prescribed to help prevent blood clots. With more than 2 million prescriptions per year, one of the side effects of the drug is an increased risk of bleeding. The FDA re-labeled yesterday the warfarin package insert recommending the testing of multiple genetic variants in two genes namely 2C9 and VKORC1 for safer drug dosing.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA